Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation

Inclusion Criteria: * Confirmed respiratory tract SARS-coV-2 infection by at least one PCR on nasopharygeal sample or a bronchoalveolar lavage * Patient hospitalized with clinical, biological and radiological features corresponding to the following stages : * Stage 2b: hypoxic pneumonia (respiratory frequency \> 30/mn, Sa02 \< 90 mmHg on room air) associated with a clear biological inflammatory syndrome (CRP \> 150 mg/l) * Stage 3: ARDS defined by a patient under mechanical ventilation with a ratio PaO2/FiO2 \< 300 for more than 24h * Evolved stage 3: ARDS according to previous definition associated with another organ failure or syndrome among: * A state of shock with noradrenaline dosing \> 3mg/h * Acute kidney failure oligo-anuric or justifying extra-renal purification * Hepatocellular insufficiency or coagulopathy with a V factor \< 50% * Myocarditis responsible for acute heart failure and or cardiogenic shock * Hemophagocytic syndrome * Hyperferritinemia \> 5000 ng/mL * Subject or legal representative having expressed written consent after information * Subject affiliated to or entitled to a social security regimen * Patient presenting in a life-threatening emergency situation that does not allow consent to be obtained Exclusion Criteria: * Pregnancy or lactation * Absolute neutrophil count less than 1.5 x 109/L * Hepatic transaminases AST or ALT greater than 5 times normal values * Platelet count less than 50,000 per mm3 * Solid organ or hematopoietic stem cell transplant patients * Patients treated with immunosuppressants or immunomodulators * Use of oral corticosteroids chronically at doses greater than 10 mg prednisone equivalent per day for a non-COVID-19 related condition. * Uncontrolled autoimmune disease * Patients with active, suspected or known, uncontrolled systemic bacterial, viral (excluding COVID-19) or fungal infections * Hypersensitivity to anakinra and/or ruxolitinib and their excipients * Vaccinations with live attenuated vaccines in the month prior to inclusion * Patients with severe pre-existing uncontrolled organ dysfunction (heart, liver or kidney failure) * Persons deprived of liberty by judicial or administrative decision or major persons under a legal protection measure. * Person in exclusion period of another research protocol for SARS-CoV-2 infection. * Person not mastering enough French understanding and reading to be able to consent to participate in the study. * Persons under psychiatric care pursuant to Articles A3112-1 and L3113-1 who are not covered by the provisions of Article L1121-8 * Every condition which, according to investigator, might increase and compromise the person security in case of study participation or might interfere with research results.